Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention

Cancer Prevention Research

Volumn 4, Issue 9, 2011, Pages 1360-1365

  Lin, Jennifer H ^a   Zhang, Shumin M ^a   Manson, JoAnn E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGING; ALCOHOL CONSUMPTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; DEPRESSION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ETHNIC DIFFERENCE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; LIFESTYLE; MIGRAINE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; SMOKING; SOCIAL STATUS; SURVIVAL RATE; TREATMENT OUTCOME; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICAL ONCOLOGY; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, ESTROGEN; RISK; SMOKING; SOCIAL CLASS; TAMOXIFEN;

EID: 80052606172     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0380     Document Type: Short Survey

References (46)

1. Lippman S.M., Brown P.H. Tamoxifen prevention of breast cancer: An instance of the fingerpost. J Natl Cancer Inst 1999;91:1809-1819
2. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467
3. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388 (Pubitemid 28439961)
4. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300. (Pubitemid 36126189)
5. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96- month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-282 (Pubitemid 47073490)
6. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662 (Pubitemid 41672231)
7. Cella D., Fallowfield L.J. Recognition and management of treatmentrelated side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167-180 (Pubitemid 350265697)
8. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L., Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-2669 (Pubitemid 29415221)
9. Grunfeld E.A., Hunter M.S., Sikka P., Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005; 59:97-102. (Pubitemid 41399883)
10. Demissie S., Silliman R.A., Lash T.L. Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-328 (Pubitemid 32112842)
11. Partridge A.H. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006;17:183-184 (Pubitemid 43160103)
12. Waterhouse D.M., Calzone K.A., Mele C., Brenner D.E. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-1197 (Pubitemid 23163362)
13. Chlebowski R.T., Geller M.L. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9.
14. Partridge A.H., Wang P.S., Winer E.P., Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-606 (Pubitemid 46621892)
15. McCowan C., Shearer J., Donnan P.T., Dewar J.A., Crilly M., Thompson A.M., et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-1768
16. Hershman D.L., Kushi L.H., Shao T., Buono D., Kershenbaum A., Tsai W.Y., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-4128
17. Barron T.I., Connolly R., Bennett K., Feely J., Kennedy M.J. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007; 109:832-839 (Pubitemid 46333524)
18. Fink A.K., Gurwitz J., Rakowski W., Guadagnoli E., Silliman R.A. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22:3309-3315 (Pubitemid 41103687)
19. Owusu C., Buist D.S., Field T.S., Lash T.L., Thwin S.S., Geiger A.M., et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26: 549-555 (Pubitemid 351264347)
20. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529-537
21. Dezentje V.O., Van Blijderveen N.J., Gelderblom H., Putter H, van Herk- Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 2010;28:2423-2429
22. Atkins L., Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006; 42:2271-2276 (Pubitemid 44307611)
23. Kahn K.L., Schneider E.C., Malin J.L., Adams J.L., Epstein A.M. Patient centered experiences in breast cancer: Predicting long-term adherence to tamoxifen use. Med Care 2007;45:431-439
24. Kimmick G., Anderson R., Camacho F., Bhosle M., Hwang W., Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009;27:3445-3451
25. Bober S.L., Hoke L.A., Duda R.B., Regan M.M., Tung N.M. Decision-making about tamoxifen in women at high risk for breast cancer: Clinical and psychological factors. J Clin Oncol 2004;22:4951-4957 (Pubitemid 46638620)
26. Pellegrini I., Sarradon-Eck A., Soussan P.B., Lacour A.C., Largillier R., Tallet A., et al. Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: Breast cancer patients' point of view. Psycho-Oncology 2010;19:472-479
27. Lash T.L., Fox M.P., Westrup J.L., Fink A.K., Silliman R.A. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99:215-220 (Pubitemid 44268270)
28. Land S.R., Wickerham D.L., Costantino J.P., Ritter M.W., Vogel V.G., Lee M., et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2742-2751
29. Land S.R., Cronin W.M., Wickerham D.L., Costantino L.P., Christian N.J., Klein W.M.P., et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res 2011;4:1393-1400
30. Maurice A., Howell A., Evans D.G., O'Neil A.C., Scobie S. Predicting compliance in a breast cancer prevention trial. Breast J 2006;12: 446-450 (Pubitemid 44337438)
31. Cronin W.M., Cecchini R.S., Wickerham D.L., Vogel V.G., Costantino J.P., Wolmark N. Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) [abstract]. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; 2008; Chicago, IL: ASCO; 2008. Abstract nr 6518.
32. Zhan M., Flaws J.A., Gallicchio L., Tkaczuk K., Lewis L.M., Royak-Schaler R. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev 2007; 31:384-390 (Pubitemid 350166794)
33. Land S.R., Christian N., Wickerham D.L., Costantino J.P., Ganz PA. Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT) [abstract]. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; 2011; Chicago, IL: ASCO; 2011. Abstract nr 1505.
34. Gronwald J., Tung N., Foulkes W.D., Offit K., Gershoni R., Daly M., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 2006;118:2281-2284
35. Narod SA. Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J Clin Oncol 2010 ;28:e698-9; author reply e700.
36. Caleffi M., Ribeiro R.A., Bedin A.J. Jr, Viegas-Butzke J.M., Baldisserotto F.D., Skonieski G.P., et al. Adherence to a breast cancer screening program and its predictors in underserved women in southern Brazil. Cancer Epidemiol Biomarkers Prev 2010;19:2673-2679
37. Gierisch J.M., Earp J.A., Brewer N.T., Rimer B.K. Longitudinal predictors of nonadherence to maintenance of mammography. Cancer Epidemiol Biomarkers Prev 2010;19:1103-1111
38. Moy B., Richardson H., Johnston D., Pater J.L., Chlebowski RT, Alés- Martínez JE, et al. NCIC CTG MAP.3: Enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Breast Cancer Res Treat 2007;106 Suppl 1:S141-S142
39. Irwin M.L., McTiernan A., Manson J.E., Thomson C.A., Sternfeld B., Stefanick M.L., et al. Physical activity and survival in postmenopausal women with breast cancer: Results from the women's health initiative. Cancer Prev Res 2011;4:522-529
40. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 2010;3:696-706.
41. Goss P.E., Ingle J.N., Ales-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-2391
42. Freedman A.N., Graubard B.I., Rao S.R., McCaskill-Stevens W., Ballard- Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-532 (Pubitemid 36511623)
43. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19: 443-446
44. Kirk M.C., Hudis C.A. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8:155-161 (Pubitemid 351655930)
45. Magai C., Consedine N.S., Adjei B.A., Hershman D., Neugut A. Psychosocial influences on suboptimal adjuvant breast cancer treatment adherence among African American women: Implications for education and intervention. Health Educ Behav 2008;35:835-854
46. Rosenzweig M., Brufsky A., Rastogi P., Puhalla S., Simon J., Underwood S. The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity. Oncol Nurs Forum 2011;38:85-89